Developing Tomorrow’s Medical Breakthrough Technologies Today
Our Mission
Supporting high impact Neuroscience research initiatives with Foundation staff and laboratory resources; and by grant awards to outstanding scientists engaged in biomedical studies at facilities in the US and overseas.
The Foundation Research Advisors are led by its President and Medical Director, Thomas Devlin, MD, PhD. Current priority areas of interest are stroke and Alzheimer’s Disease. Healthcare Economics is another area of study.
In addition to a research Mission, the Foundation supports professional medical education and lecture programs by outstanding research scientists and clinicians. Another key aspect of the Foundation Mission Statement is the encouragement of Jobs and Community economic development by facilitating the creation of urban biotech districts. And finally, the Foundation also provides grants for hospitals to purchase advanced medical equipment for their Neurology service lines.
A Message from Our President
and Chief Medical Officer
Thomas G. Devlin, MD, PhD
President and Chief Medical Officer
NeuroScience Innovation Foundation
Greetings and Welcome
Please join me and my colleagues at the NeuroScience Innovation Foundation in advancing frontiers of medicine. It’s very exciting for all of us to have launched the Foundation in late 2020 and for donors to have stepped forward to fund initial projects.
Stroke is an area of early interest with Alzheimer’s dementia emerging as a pathology where new disease models based on brilliant neurobiology may, at long last, offer some crucial breakthroughs.
Projects and research the Foundation is looking to initiate in the Neuroscience arena are diverse in scope.
VALIDATE: The Largest Study of its Kind
Assessing the impact of artificial intelligence (AI)-based medical technology was conceived by Dr. Thomas Devlin, Medical Director of the NeuroScience Innovation Foundation.
The key finding from VALIDATE is that that a
AI-based cell-phone app called VIZ.ai, reduces the time it takes for a patient to be diagnosed with an ischemic stroke by 44%
compared to cases where an AI product was not used. That comparative advantage translates into much faster “time to treatment” in a stroke emergency, and this often results in greatly enhanced medical outcomes.
The 2023 Foundation Research Agenda includes these items
Alzheimers and Dementia Research
The NeuroScience Innovation Foundation has been very active in supporting exciting Alzheimer’s and Dementia Research.
Music Therapy Research
to hasten and advance recovery from neurologic disease.
The Lab
to design and test stroke intervention devices.
Healthcare Economics
studies on stroke therapies performed in collaboration with local academics.
Chattanooga Bio-Tech Strategic Planning and Community Development
to route patients to appropriate levels of emergency intervention care.
.
National and Regional Professional Education
events for physicians and nurses.
Center for Precision Medicine
This is a brand new discipline that designs medical therapies tailored to individual genetic and personal history. We’ve gathered a team of local experts to evaluate and help implement Precision Medicine programs..
Targeted Gifts for Clinical Care
tele-medicine equipment, stroke nurse training and video streaming systems.
Meet Our Officers
THOMAS DEVLIN MD, PhD
President and Medical Director
Dr. Thomas Devlin is world-renowned for his research in acute ischemic stroke with over twenty years of experience as a vascular neurologist Currently, he is the Director of the Chattanooga-based CHI–Memorial Stroke & Neuroscience Center, part of the national organization Common Spirit.
Prior to his CHI-Memorial appointment Dr. Devlin served as the Chairman of the Department of Neurology for over 10 years at the University of Tennessee College of Medicine, Chattanooga, and is currently on faculty there as a full professor of Neurology.
As the Neurology Department Chair and Medical Director of the Clinical Program at Erlanger Health System, Dr. Devlin recruited a team of eminent stroke Neurologists and Interventional Radiologists becoming one of the largest and most highly respected stroke treatment facilities worldwide.
He is the Founder and Director of the Chattanooga Center for Neurologic Research (CCNR), a private research company, serving as well as the President and Medical Director of the NeuroScience Innovation Foundation. As the director of CCNR, Dr. Devlin has published more than a dozen articles on acute stroke treatment and with Dr. Blaise Baxter, he authored the first single-center confirmation of the clinical benefit of advanced stroke thrombectomy procedures using the MERCI device. His center was the highest enrolling center and the center demonstrating the very best patient outcomes worldwide in the landmark SWIFT-PRIME study that proved the benefit of endovascular therapy for stroke over IV tPA.
As the director of the Chattanooga Center for Neurologic Research, Dr. Devlin has developed Erlanger hospital into a testbed center for translational research for high-tech, cutting-edge, stroke treatments in partnership with biotech companies from around the world. Dr. Devlin has been a Principal Investigator on over 60 major clinical trials of new thrombolytic, neuroprotectant, stem-cell, and device therapies for acute stroke. He currently serves as the national principal investigator for the LUMOSA trial of a novel thrombolytic medication. In partnership with Dr. Peter Hunt, an otolaryngologist from Chattanooga, he helped pioneer the use of the Brainsgate surgical device, and its telemedicine-based navigation system, for intracranial arterial dilation in acute stroke patients. And as the director of the leading American site in the Brainsgate trial, the technology is now pending full FDA approval. More recently, Dr. Devlin has been instrumental in the FDA approval of two new artificial intelligence-based technologies: Viz.ai and NovaSignal. Dr. Devlin was the lead clinician in the development of these technologies and his center was the first hospital to acquire both technologies once fully commercialized. He is now the national principal investigator on the DISTINCTION trial designed to prove the clinical benefit of Viz.ai.
Dr. Devlin is founder and currently the Medical Director of the Neuroscience Innovation Foundation, a medical nonprofit corporation supporting research and clinical care in Neuroscience.
Previously, Dr. Devlin was the Founder of the non-profit Pleiades Foundation for Advanced Neuro-Medical Education which provided medical education to physicians and administrators throughout the world on both the clinical and financial aspects of stroke center development. The activities of the Pleiades Foundation were assumed by Erlanger Health System in 2016.
Dr. Devlin served as the National Program Co-Chair of the International Society for Vascular and Interventional Neurology in 2017 and 2018 and was awarded a fellowship from that society.
Thomas Devlin earned his medical degree from Baylor College of Medicine in 1991, completed a residency in Neurology at Duke University in 1995, and a fellowship in neurocritical care at the University of Virginia in 1996 with the father of neurocritical care, Dr. Thomas Bleck.
PETER CATALANO
Treasurer/ CEO
Peter Catalano has collaborated with Dr. Devlin for many years. Prior to founding the NeuroScience Innovation with Devlin, Peter was CEO of the Pleiades Foundation, a non-profit corporation the provided advanced neuromedical education to an international audience of physicians and hospital administrators. Over the years, the Pleaides enrolled more than 700 attendees to study Stroke Neurointerventional medical procedures and Stroke Center Operations and Finances. Peter Catalano played a pivotal role in forging cooperative relations between medical clinicians and industry innovators. Earlier in his career Peter worked on advanced engineering research into robot-based assembly systems at MIT-affiliated Charles Stark Draper Laboratories in Cambridge, MA. For several years Peter was also a science journalist covering everything from astrophysics to theoretical biology and hurricane forecasting. Peter is a graduate of Columbia College in New York City majoring in Economics with a minor degree in Philosophy.
MARTHA SUMMA-CHADWICK, DMA
Research Associate/ Music Therapy
DAVID PORTER
Corporate Secretary
David Porter has worked for almost two decades in the field of visual merchandising as both a designer and engineer. He is currently director of engineering for the health & beauty division at Marketing Alliance Group in Dalton, GA. His client facing role involves proving design and manufacturing solutions for retailers Sephora and Ulta Beauty as well as over a dozen prestige cosmetic brands. Over the years he has worked with a wide array of Fortune 500 retailers in the grocery, convenient and department store environments. David is a graduate of the University of Michigan with a major in Industrial Design and a minor in Art History.
Contact Us
Developing Tomorrow’s Medical Breakthrough Technologies Today
© NeuroScience Innovation Foundation 2023
web design by Mark Devlin Visual Design www.md-visualdesign.com